CLINICAL STUDIES ON AZTHREONAM

• Published in: CHEMOTHERAPY Vol. 33; no. Supplement1; pp. 389 - 394
• Main Authors: KOBAYASHI, HIROYUKI, TAKAMURA, KENJI, KOHNO, KOHTA, OSHITANI, HIROSHI, TAKEDA, HIROAKI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1985
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.33.Supplement1_389

Azthreonam, one of the monobactam β-lactam antibiotic, was studied to determine clinical efficacy and safety by the intravenous route in 23 patients with respiratory infections (14 chronic bronchitis and 2 pneumonia), 5 with septicemia and 2 with urinary tract infections. Included were patients in which gram-negative bacteria were identified as the pathogen as well as patients in which infections caused by gram-negative bacteria were uncertain. Many patients were considered difficult to refractory even for reasons such as failure to respond to previous treatment, presence of delayed infection and finally advanced age. The therapeutic results were good in 16 of 23 patients with respiratory infections (efficacy rate 70%), in all 5 patients with septicemia and in both patients with urinary tract infections. No side-effects were observed. The GOT and GPT values were elevated in 2 patients and the BUN in one. All elevated values were transient. The above results suggest that Azthreonam is a useful antibiotic for the treatment of respiratory infections caused by gram-negative rods and for the treatment of gram-negative septicemia. There is a need to study dosage levels and periods for efficacy in the treatment of respiratory infections caused by Pseudomonas. Azthreonam is an efficacious antibiotic that deserves further evaluation.